In Vivo Molecular Imaging of Neuroinflammation in Alzheimer's Disease

Overview

Journal J Neurochem

Specialties Chemistry
Neurology

Date 2018 Oct 20

PMID 30339715

Citations 50

Authors

Aisling Chaney

Steve R Williams

Herve Boutin

Affiliations

Soon will be listed here.

Abstract

It has become increasingly evident that neuroinflammation plays a critical role in the pathophysiology of Alzheimer's disease (AD) and other neurodegenerative disorders. Increased glial cell activation is consistently reported in both rodent models of AD and in AD patients. Moreover, recent genome wide association studies have revealed multiple genes associated with inflammation and immunity are significantly associated with an increased risk of AD development (e.g. TREM2). Non-invasive in vivo detection and tracking of neuroinflammation is necessary to enhance our understanding of the contribution of neuroinflammation to the initiation and progression of AD. Importantly, accurate methods of quantifying neuroinflammation may aid early diagnosis and serve as an output for therapeutic monitoring and disease management. This review details current in vivo imaging biomarkers of neuroinflammation being explored and summarizes both pre-clinical and clinical results from molecular imaging studies investigating the role of neuroinflammation in AD, with a focus on positron emission tomography and magnetic resonance spectroscopy (MRS).

Citing Articles

Phosphodiesterase 4 Inhibition in Neuropsychiatric Disorders Associated with Alzheimer's Disease.

Chen J, Zhu Z, Xu F, Dou B, Sheng Z, Xu Y Cells. 2025; 14(3).

PMID: 39936956 PMC: 11816594. DOI: 10.3390/cells14030164.

Mapping the current trends and hotspots of extracellular vesicles in Alzheimer's disease: a bibliometric analysis.

Xing X, Liu H, Zhang M, Li Y Front Aging Neurosci. 2025; 16:1485750.

PMID: 39759397 PMC: 11697149. DOI: 10.3389/fnagi.2024.1485750.

Association Between the Gut Microbiota and Alzheimer's Disease: An Update on Signaling Pathways and Translational Therapeutics.

Kulkarni R, Kumari S, Dhapola R, Sharma P, Singh S, Medhi B Mol Neurobiol. 2024; 62(4):4499-4519.

PMID: 39460901 DOI: 10.1007/s12035-024-04545-2.

Inflammatory Burden Index (IBI) and Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score in Alzheimer's Disease: A Retrospective Comparative Study.

Gurbuzer N, Ozkaya A Cureus. 2024; 16(9):e69148.

PMID: 39398776 PMC: 11467697. DOI: 10.7759/cureus.69148.

Inhibition of neuroinflammation and neuronal damage by the selective non-steroidal ERβ agonist AC-186.

Katola F, Adana M, Olajide O Inflamm Res. 2024; 73(12):2109-2121.

PMID: 39361032 PMC: 11632062. DOI: 10.1007/s00011-024-01952-y.

References

Nee L, Lippa C . Alzheimer's disease in 22 twin pairs--13-year follow-up: hormonal, infectious and traumatic factors. Dement Geriatr Cogn Disord. 1999; 10(2):148-51. DOI: 10.1159/000017115. View

Rose S, de Zubicaray G, Wang D, Galloway G, Chalk J, Eagle S . A 1H MRS study of probable Alzheimer's disease and normal aging: implications for longitudinal monitoring of dementia progression. Magn Reson Imaging. 1999; 17(2):291-9. DOI: 10.1016/s0730-725x(98)00168-4. View

Cagnin A, Brooks D, Kennedy A, Gunn R, Myers R, Turkheimer F . In-vivo measurement of activated microglia in dementia. Lancet. 2001; 358(9280):461-7. DOI: 10.1016/S0140-6736(01)05625-2. View

Huang W, Alexander G, Chang L, Shetty H, Krasuski J, Rapoport S . Brain metabolite concentration and dementia severity in Alzheimer's disease: a (1)H MRS study. Neurology. 2001; 57(4):626-32. DOI: 10.1212/wnl.57.4.626. View

Brown R, Papadopoulos V . Role of the peripheral-type benzodiazepine receptor in adrenal and brain steroidogenesis. Int Rev Neurobiol. 2001; 46:117-43. DOI: 10.1016/s0074-7742(01)46061-2. View

Agdeppa E, Kepe V, Liu J, Flores-Torres S, Satyamurthy N, Petric A . Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J Neurosci. 2001; 21(24):RC189. PMC: 6763047. View

Banati R . Visualising microglial activation in vivo. Glia. 2002; 40(2):206-217. DOI: 10.1002/glia.10144. View

Hayes A, Thaker U, Iwatsubo T, Pickering-Brown S, Mann D . Pathological relationships between microglial cell activity and tau and amyloid beta protein in patients with Alzheimer's disease. Neurosci Lett. 2002; 331(3):171-4. DOI: 10.1016/s0304-3940(02)00888-1. View

Perry V, Newman T, Cunningham C . The impact of systemic infection on the progression of neurodegenerative disease. Nat Rev Neurosci. 2003; 4(2):103-12. DOI: 10.1038/nrn1032. View

10.

Holmes C, El-Okl M, Williams A, Cunningham C, Wilcockson D, Perry V . Systemic infection, interleukin 1beta, and cognitive decline in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2003; 74(6):788-9. PMC: 1738504. DOI: 10.1136/jnnp.74.6.788. View

11.

Dedeoglu A, Choi J, Cormier K, Kowall N, Jenkins B . Magnetic resonance spectroscopic analysis of Alzheimer's disease mouse brain that express mutant human APP shows altered neurochemical profile. Brain Res. 2004; 1012(1-2):60-5. DOI: 10.1016/j.brainres.2004.02.079. View

12.

Kropholler M, Boellaard R, Schuitemaker A, van Berckel B, Luurtsema G, Windhorst A . Development of a tracer kinetic plasma input model for (R)-[11C]PK11195 brain studies. J Cereb Blood Flow Metab. 2005; 25(7):842-51. DOI: 10.1038/sj.jcbfm.9600092. View

13.

Nimmerjahn A, Kirchhoff F, Helmchen F . Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science. 2005; 308(5726):1314-8. DOI: 10.1126/science.1110647. View

14.

Marjanska M, Curran G, Wengenack T, Henry P, Bliss R, Poduslo J . Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. Proc Natl Acad Sci U S A. 2005; 102(33):11906-10. PMC: 1188012. DOI: 10.1073/pnas.0505513102. View

15.

Kitazawa M, Oddo S, Yamasaki T, Green K, LaFerla F . Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci. 2005; 25(39):8843-53. PMC: 6725603. DOI: 10.1523/JNEUROSCI.2868-05.2005. View

16.

Town T, Nikolic V, Tan J . The microglial "activation" continuum: from innate to adaptive responses. J Neuroinflammation. 2005; 2:24. PMC: 1298325. DOI: 10.1186/1742-2094-2-24. View

17.

Papadopoulos V, Lecanu L, Brown R, Han Z, Yao Z . Peripheral-type benzodiazepine receptor in neurosteroid biosynthesis, neuropathology and neurological disorders. Neuroscience. 2005; 138(3):749-56. DOI: 10.1016/j.neuroscience.2005.05.063. View

18.

Craft J, Watterson D, Van Eldik L . Human amyloid beta-induced neuroinflammation is an early event in neurodegeneration. Glia. 2005; 53(5):484-90. DOI: 10.1002/glia.20306. View

19.

Fujimura Y, Ikoma Y, Yasuno F, Suhara T, Ota M, Matsumoto R . Quantitative analyses of 18F-FEDAA1106 binding to peripheral benzodiazepine receptors in living human brain. J Nucl Med. 2006; 47(1):43-50. View

20.

Kropholler M, Boellaard R, Schuitemaker A, Folkersma H, van Berckel B, Lammertsma A . Evaluation of reference tissue models for the analysis of [11C](R)-PK11195 studies. J Cereb Blood Flow Metab. 2006; 26(11):1431-41. DOI: 10.1038/sj.jcbfm.9600289. View